Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets: Functional ex vivo and in vivo studies

Tzu Yin Lee, Chao Chien Chang, Wan-Jung Lu, Ting Lin Yen, Kuan Hung Lin, Pitchairaj Geraldine, Jiun Yi Li, Joen-Rong Sheu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Honokiol, derived from Magnolia officinalis, has various pharmacological properties. Platelet activation plays a critical role in cardiovascular diseases. Honokiol has been reported to inhibit collagen-stimulated rabbit platelet aggregation. However, detailed further studies on the characteristics and functional activity of honokiol in platelet activation are relatively lacking. In the present study, honokiol specifically inhibited platelet aggregation and Ca+2 ion mobilization stimulated with collagen or convulxin, an agonist of glycoprotein (GP) VI, but not with aggretin, an agonist of integrin α2β1. Honokiol also attenuated the phosphorylation of Lyn, PLCγ2, PKC, MAPKs, and Akt after convulxin stimulation. Honokiol have no cytotoxicity in zebrafish embryos. Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation. The surface plasmon resonance results revealed that honokiol binds directly to GP VI, with a KD of 289 μM. Platelet function analysis revealed that honokiol substantially prolonged the closure time in human whole blood and increased the occlusion time of thrombotic platelet plug formation in mice. In conclusion, honokiol acts as a potent antagonist of collagen GP VI in human platelets, and it has therapeutic potential in the prevention of the pathological thrombosis.

Original languageEnglish
Article number40002
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - Jan 5 2017

Fingerprint

Collagen Receptors
Glycoproteins
Blood Platelets
Collagen
Platelet Activation
Platelet Aggregation
Magnolia
honokiol
Surface Plasmon Resonance
Fluorescein-5-isothiocyanate
Zebrafish
Integrins
Thrombosis
Cardiovascular Diseases
Embryonic Structures
Phosphorylation

ASJC Scopus subject areas

  • General

Cite this

Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets : Functional ex vivo and in vivo studies. / Lee, Tzu Yin; Chang, Chao Chien; Lu, Wan-Jung; Yen, Ting Lin; Lin, Kuan Hung; Geraldine, Pitchairaj; Li, Jiun Yi; Sheu, Joen-Rong.

In: Scientific Reports, Vol. 7, 40002, 05.01.2017.

Research output: Contribution to journalArticle

Lee, Tzu Yin ; Chang, Chao Chien ; Lu, Wan-Jung ; Yen, Ting Lin ; Lin, Kuan Hung ; Geraldine, Pitchairaj ; Li, Jiun Yi ; Sheu, Joen-Rong. / Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets : Functional ex vivo and in vivo studies. In: Scientific Reports. 2017 ; Vol. 7.
@article{f0813af7a90549709ae6f56b98e15704,
title = "Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets: Functional ex vivo and in vivo studies",
abstract = "Honokiol, derived from Magnolia officinalis, has various pharmacological properties. Platelet activation plays a critical role in cardiovascular diseases. Honokiol has been reported to inhibit collagen-stimulated rabbit platelet aggregation. However, detailed further studies on the characteristics and functional activity of honokiol in platelet activation are relatively lacking. In the present study, honokiol specifically inhibited platelet aggregation and Ca+2 ion mobilization stimulated with collagen or convulxin, an agonist of glycoprotein (GP) VI, but not with aggretin, an agonist of integrin α2β1. Honokiol also attenuated the phosphorylation of Lyn, PLCγ2, PKC, MAPKs, and Akt after convulxin stimulation. Honokiol have no cytotoxicity in zebrafish embryos. Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation. The surface plasmon resonance results revealed that honokiol binds directly to GP VI, with a KD of 289 μM. Platelet function analysis revealed that honokiol substantially prolonged the closure time in human whole blood and increased the occlusion time of thrombotic platelet plug formation in mice. In conclusion, honokiol acts as a potent antagonist of collagen GP VI in human platelets, and it has therapeutic potential in the prevention of the pathological thrombosis.",
author = "Lee, {Tzu Yin} and Chang, {Chao Chien} and Wan-Jung Lu and Yen, {Ting Lin} and Lin, {Kuan Hung} and Pitchairaj Geraldine and Li, {Jiun Yi} and Joen-Rong Sheu",
year = "2017",
month = "1",
day = "5",
doi = "10.1038/srep40002",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets

T2 - Functional ex vivo and in vivo studies

AU - Lee, Tzu Yin

AU - Chang, Chao Chien

AU - Lu, Wan-Jung

AU - Yen, Ting Lin

AU - Lin, Kuan Hung

AU - Geraldine, Pitchairaj

AU - Li, Jiun Yi

AU - Sheu, Joen-Rong

PY - 2017/1/5

Y1 - 2017/1/5

N2 - Honokiol, derived from Magnolia officinalis, has various pharmacological properties. Platelet activation plays a critical role in cardiovascular diseases. Honokiol has been reported to inhibit collagen-stimulated rabbit platelet aggregation. However, detailed further studies on the characteristics and functional activity of honokiol in platelet activation are relatively lacking. In the present study, honokiol specifically inhibited platelet aggregation and Ca+2 ion mobilization stimulated with collagen or convulxin, an agonist of glycoprotein (GP) VI, but not with aggretin, an agonist of integrin α2β1. Honokiol also attenuated the phosphorylation of Lyn, PLCγ2, PKC, MAPKs, and Akt after convulxin stimulation. Honokiol have no cytotoxicity in zebrafish embryos. Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation. The surface plasmon resonance results revealed that honokiol binds directly to GP VI, with a KD of 289 μM. Platelet function analysis revealed that honokiol substantially prolonged the closure time in human whole blood and increased the occlusion time of thrombotic platelet plug formation in mice. In conclusion, honokiol acts as a potent antagonist of collagen GP VI in human platelets, and it has therapeutic potential in the prevention of the pathological thrombosis.

AB - Honokiol, derived from Magnolia officinalis, has various pharmacological properties. Platelet activation plays a critical role in cardiovascular diseases. Honokiol has been reported to inhibit collagen-stimulated rabbit platelet aggregation. However, detailed further studies on the characteristics and functional activity of honokiol in platelet activation are relatively lacking. In the present study, honokiol specifically inhibited platelet aggregation and Ca+2 ion mobilization stimulated with collagen or convulxin, an agonist of glycoprotein (GP) VI, but not with aggretin, an agonist of integrin α2β1. Honokiol also attenuated the phosphorylation of Lyn, PLCγ2, PKC, MAPKs, and Akt after convulxin stimulation. Honokiol have no cytotoxicity in zebrafish embryos. Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation. The surface plasmon resonance results revealed that honokiol binds directly to GP VI, with a KD of 289 μM. Platelet function analysis revealed that honokiol substantially prolonged the closure time in human whole blood and increased the occlusion time of thrombotic platelet plug formation in mice. In conclusion, honokiol acts as a potent antagonist of collagen GP VI in human platelets, and it has therapeutic potential in the prevention of the pathological thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=85008612415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008612415&partnerID=8YFLogxK

U2 - 10.1038/srep40002

DO - 10.1038/srep40002

M3 - Article

AN - SCOPUS:85008612415

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 40002

ER -